Company Overview and News

4
ZOES / Zoe's Kitchen, Inc. DEFM14A

2018-10-10 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS
ZOES

4
Are Options Traders Betting on a Big Move in Zoe's Kitchen (ZOES) Stock?

2018-10-03 zacks
Investors in Zoe’s Kitchen, Inc. (ZOES - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 18, 2019 $10.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
EMN ZOES

4
ZOES / Zoe's Kitchen, Inc. PREM14A

2018-09-25 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS
ZOES

247
Stocks To Watch: Oracle Looks To Lift Tech Sector

2018-09-15 seekingalpha - 5
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
DOVA GIS TXN CAT AZO TWX RCL OPRF MAS HABT SHAK SUM BOX SONC RCII ABBV USCR FOX REGN BAC SQ DFS TRV COF-P WK BX JACK SYF AIG WEN ALL IDA KNSA NVS ABBV MSFT FL ZOES PFE ADS FOXA MLM JD NIO ATH DRI CX PYPL AXP MCO JBHT BRO EXP USB BAC COF-D COF-C COF-F HIG AAPL VMC TSG ORCL DEO MCD BMY RRGB WBC C CMCSA O THO MA M COF FDX NAVG HUM SNY RHT DSKE JPM IBOC MU DHR

4
ZOES / Zoe's Kitchen, Inc. / JP Morgan Chase & Co - NONE (Passive Investment)

2018-09-07 sec.gov
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION
ZOES

4
ZOES / Zoe's Kitchen, Inc. / JP Morgan Chase & Co - NONE (Passive Investment)

2018-09-07 sec.gov
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION
ZOES

31
Bulletproof Investing Performance Update: Week 40

2018-09-05 seekingalpha
It's been six months since I presented four hedged portfolios and 10 top names in week 40 of my Marketplace service (March 1). Here's how everything did.
SQ CMA MA NFLX CXO LPSN ANET ASGN WWE TWTR ABBV ZOES INTC ABBV EBAY

4
Habit: Heading Higher

2018-08-30 seekingalpha
Habit has seen a 50% rally in the last quarter based on a limited improvement in comp sales.
HABT ZOES

29
7 Best Restaurant Stocks to Bite Into Today

2018-08-30 investorplace
In this bull market, investors have clearly preferred growth stocks to value stocks. But they’ve been reasonably hot toward restaurant stocks, too.
YUM EAT YUMC BWLD PBPB CHUY QSR.WI SHAK HABT FRGI MSFT PLAY DIN ZOES QSR WING MCD DPZ PZZA

5
A More Appetizing Offer Could Boost Zoe’s Kitchen Stock

2018-08-21 investorplace
Investors had been looking forward to earnings from Zoe’s Kitchen (NYSE:ZOES) last week. Instead, the company’s earnings were delayed., and ZOES surprised investors by announcing that it had received a buyout offer. If the proposed deal goes through, a private restaurant chain will acquire all outstanding ZOES stock for $12.75 per share.
HABT EAT DIN ZOES CMG

4
ZOES / Zoe's Kitchen, Inc. / Pw Partners Atlas Funds, Llc - SCHEDULE 13D (Activist Investment)

2018-08-21 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D
ZOES

4
ZOES / Zoe's Kitchen, Inc. / Pw Partners Atlas Funds, Llc - SCHEDULE 13D (Activist Investment)

2018-08-21 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D
ZOES

4
Zoe's Kitchen to go Private After Merger Agreement With CAVA

2018-08-20 zacks
Zoe's Kitchen, Inc. (ZOES - Free Report) has announced that it signed a definitive merger agreement under which it will be acquired by a privately held Mediterranean culinary brand, Cava Group, Inc. The acquisition is slated to be financed by Act III Holdings. Both the companies expect to close the merger deal in the fourth quarter of 2018. Shares of Zoe’s Kitchen have increased 33.3% during the trading session on Aug 17, on the day of the declaration of the news.
ZOES TAST

4
ZOES / Zoe's Kitchen, Inc. 8-K

2018-08-20 sec.gov
UNITED STATES
ZOES

4
ZOES / Zoe's Kitchen, Inc. 8-K (Current Report)

2018-08-20 sec.gov
UNITED STATES
ZOES

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 98979J109